ENANTIGEN THERAPEUTICS, INC.

Basic Information

3805 OLD EASTON RD
DOYLESTOWN, PA, 18902-8400

http://enantigen.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 828761697
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 10


  1. Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga

    Amount: $294,674.00

    DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Neural Probe for high spatial and temporal resolution detection of cocaine and su

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): This is a proposal to implement a novel high throughput assay system to detect inhibitors of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) format ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

    Amount: $738,292.00

    This project builds on patterns derived from natural antimicrobial peptide sequences to develop novel compounds with better systemic activity, lower cytotoxicity and broader spectrum activity against ...

    STTR Phase II 2012 ArmyDepartment of DefenseDepartment of Defense
  5. Development of a Therapy for Dengue Virus Infection

    Amount: $282,480.00

    DESCRIPTION (provided by applicant): This is a Phase I proposal to develop a new family of imino sugars, with break through , unprecedented, potency, for the treatment of dengue virus (DENV) infectio ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

    Amount: $99,967.00

    This project addresses two pressing problems in treating bacterial infections: the emerging resistance against current antibiotics and the role of biofilm formation in these infections. Based ona succ ...

    STTR Phase I 2009 Defense Advanced Research Projects AgencyDepartment of DefenseDepartment of Defense

Agency Micro-sites

US Flag An Official Website of the United States Government